Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections

Peter B. Jahrling, Thomas Geisbert, J. B. Geisbert, J. R. Swearengen, M. Bray, N. K. Jaax, J. W. Huggins, James LeDuc, C. J. Peters

Research output: Contribution to journalArticle

223 Citations (Scopus)

Abstract

A passive immunization strategy for treating Ebola virus infections was evaluated using BALB/c mice, strain 13 guinea pigs, and cynomolgus monkeys. Guinea pigs were completely protected by injection of hyperimmune equine IgG when treatment was initiated early but not after viremia had developed. In contrast, mice were incompletely protected even when treatment was initiated on day 0, the day of virus inoculation. In monkeys treated with one dose of IgG on day 0, onset of illness and viremia was delayed, but all treated animals died. A second dose of IgG on day 5 had no additional beneficial effect. Pretreatment of monkeys delayed onset of viremia and delayed death several additional days. Interferon-α2b (2 x 107 IU/kg/day) had a similar effect in monkeys, delaying viremia and death by only several days. Effective treatment of Ebola infections may require a combination of drugs that inhibit vital replication in monocyte/macrophage-like cells while reversing the pathologic effects (e.g, coagulopathy) consequent to this replication.

Original languageEnglish (US)
JournalJournal of Infectious Diseases
Volume179
Issue numberSUPPL. 1
StatePublished - 1999
Externally publishedYes

Fingerprint

Ebola Hemorrhagic Fever
Viremia
Interferons
Immunoglobulins
Haplorhini
Immunoglobulin G
Guinea Pigs
Passive Immunization
Macaca fascicularis
Drug Combinations
Therapeutics
Horses
Monocytes
Macrophages
Viruses
Injections

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Jahrling, P. B., Geisbert, T., Geisbert, J. B., Swearengen, J. R., Bray, M., Jaax, N. K., ... Peters, C. J. (1999). Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections. Journal of Infectious Diseases, 179(SUPPL. 1).

Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections. / Jahrling, Peter B.; Geisbert, Thomas; Geisbert, J. B.; Swearengen, J. R.; Bray, M.; Jaax, N. K.; Huggins, J. W.; LeDuc, James; Peters, C. J.

In: Journal of Infectious Diseases, Vol. 179, No. SUPPL. 1, 1999.

Research output: Contribution to journalArticle

Jahrling, PB, Geisbert, T, Geisbert, JB, Swearengen, JR, Bray, M, Jaax, NK, Huggins, JW, LeDuc, J & Peters, CJ 1999, 'Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections', Journal of Infectious Diseases, vol. 179, no. SUPPL. 1.
Jahrling, Peter B. ; Geisbert, Thomas ; Geisbert, J. B. ; Swearengen, J. R. ; Bray, M. ; Jaax, N. K. ; Huggins, J. W. ; LeDuc, James ; Peters, C. J. / Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections. In: Journal of Infectious Diseases. 1999 ; Vol. 179, No. SUPPL. 1.
@article{94c0688e804a4d3a812caa5ff246157d,
title = "Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections",
abstract = "A passive immunization strategy for treating Ebola virus infections was evaluated using BALB/c mice, strain 13 guinea pigs, and cynomolgus monkeys. Guinea pigs were completely protected by injection of hyperimmune equine IgG when treatment was initiated early but not after viremia had developed. In contrast, mice were incompletely protected even when treatment was initiated on day 0, the day of virus inoculation. In monkeys treated with one dose of IgG on day 0, onset of illness and viremia was delayed, but all treated animals died. A second dose of IgG on day 5 had no additional beneficial effect. Pretreatment of monkeys delayed onset of viremia and delayed death several additional days. Interferon-α2b (2 x 107 IU/kg/day) had a similar effect in monkeys, delaying viremia and death by only several days. Effective treatment of Ebola infections may require a combination of drugs that inhibit vital replication in monocyte/macrophage-like cells while reversing the pathologic effects (e.g, coagulopathy) consequent to this replication.",
author = "Jahrling, {Peter B.} and Thomas Geisbert and Geisbert, {J. B.} and Swearengen, {J. R.} and M. Bray and Jaax, {N. K.} and Huggins, {J. W.} and James LeDuc and Peters, {C. J.}",
year = "1999",
language = "English (US)",
volume = "179",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections

AU - Jahrling, Peter B.

AU - Geisbert, Thomas

AU - Geisbert, J. B.

AU - Swearengen, J. R.

AU - Bray, M.

AU - Jaax, N. K.

AU - Huggins, J. W.

AU - LeDuc, James

AU - Peters, C. J.

PY - 1999

Y1 - 1999

N2 - A passive immunization strategy for treating Ebola virus infections was evaluated using BALB/c mice, strain 13 guinea pigs, and cynomolgus monkeys. Guinea pigs were completely protected by injection of hyperimmune equine IgG when treatment was initiated early but not after viremia had developed. In contrast, mice were incompletely protected even when treatment was initiated on day 0, the day of virus inoculation. In monkeys treated with one dose of IgG on day 0, onset of illness and viremia was delayed, but all treated animals died. A second dose of IgG on day 5 had no additional beneficial effect. Pretreatment of monkeys delayed onset of viremia and delayed death several additional days. Interferon-α2b (2 x 107 IU/kg/day) had a similar effect in monkeys, delaying viremia and death by only several days. Effective treatment of Ebola infections may require a combination of drugs that inhibit vital replication in monocyte/macrophage-like cells while reversing the pathologic effects (e.g, coagulopathy) consequent to this replication.

AB - A passive immunization strategy for treating Ebola virus infections was evaluated using BALB/c mice, strain 13 guinea pigs, and cynomolgus monkeys. Guinea pigs were completely protected by injection of hyperimmune equine IgG when treatment was initiated early but not after viremia had developed. In contrast, mice were incompletely protected even when treatment was initiated on day 0, the day of virus inoculation. In monkeys treated with one dose of IgG on day 0, onset of illness and viremia was delayed, but all treated animals died. A second dose of IgG on day 5 had no additional beneficial effect. Pretreatment of monkeys delayed onset of viremia and delayed death several additional days. Interferon-α2b (2 x 107 IU/kg/day) had a similar effect in monkeys, delaying viremia and death by only several days. Effective treatment of Ebola infections may require a combination of drugs that inhibit vital replication in monocyte/macrophage-like cells while reversing the pathologic effects (e.g, coagulopathy) consequent to this replication.

UR - http://www.scopus.com/inward/record.url?scp=0033066490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033066490&partnerID=8YFLogxK

M3 - Article

C2 - 9988188

AN - SCOPUS:0033066490

VL - 179

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - SUPPL. 1

ER -